Ad
related to: her2 gastric cancer interpretation- Request a Rep
Request a Representative to Learn
More About This Treatment Option.
- Efficacy & Safety
View Response Data, Study Design,
& Safety Data for Phase 3 Trials.
- Dosing and Admin
View Recommended Dosing and
Administration Information.
- Biomarker Testing
See How Testing Reveals a Prevalent
Target for First-Line Treatment.
- Request a Rep
Search results
Results from the WOW.Com Content Network
Over-expression is also known to occur in ovarian, [19] stomach, adenocarcinoma of the lung [20] and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma, [21] [22] e.g. HER2 is over-expressed in approximately 7-34% of patients with gastric cancer [23] [24] and in 30% of salivary duct carcinomas.
The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer. [6]
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [30] [27] [31] [32] It is specifically used for cancer that is HER2 receptor positive. [30] It may be used by itself or together with other chemotherapy medication. [30]
For instance, some stomach cancers express a gene called HER2, which is also linked to breast cancer. “The drugs that work in HER2 breast cancer to some degree work in HER2 gastric cancer.
Cohort of 80 Breast Cancer Samples HRDetect was tested in 80 breast cancer cases with mainly ER positive and HER2 negative. The tool was able to find ones that exceed HRDetect score 0.7, including one germline BRCA1 mutation carrier, four germline BRCA2 mutation carriers and one somatic BRCA2 mutation carrier.
a phase III trial for HER2+ gastric cancer compares T-DM1 to physician's choice of taxane (docetaxel or paclitaxel). [35] On 22 October 2015, Roche and co-developer ImmunoGen disclosed that trastuzumab emtansine had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2 -positive ...
] The highest rate of stomach cancer was in Mongolia, at 28 cases per 100,000 people. [105] [unreliable source?] In the United Kingdom, stomach cancer is the 15th most-common cancer (around 7,100 people were diagnosed with stomach cancer in 2011), and it is the 10th most-common cause of cancer-related deaths (around 4,800 people died in 2012 ...
All four ErbB receptor family members are nearly same in the structure having single-chain of modular glycoproteins. [4] This structure is made up of an extracellular region or ectodomain or ligand binding region that contains approximately 620 amino acids, a single transmembrane-spanning region containing approximately 23 residues, and an intracellular cytoplasmic tyrosine kinase domain ...
Ad
related to: her2 gastric cancer interpretation